LISI Group in Exclusive Talks with SK Capital to Sell Medical Division
Deal News | Jul 09, 2025 | SK Capital
SK Capital Partners, a private investment firm specializing in specialty materials, ingredients, and life sciences, has entered into exclusive negotiations to acquire LISI Group’s Medical division. The acquisition is contingent upon several regulatory approvals and consultations, with the transaction expected to close in the latter half of 2025. Lisi Medical specializes in producing high-precision metal components for global medical device OEMs and has made significant technological investments under LISI Group's ownership. SK Capital plans to accelerate the growth of Lisi Medical through its transformational growth strategy, leveraging its experience in the life sciences CDMO sector. Legal and financial advisory for the transaction includes Kirkland & Ellis, Piper Sandler & Co., Jefferies LLC, and Sycomore Corporate Finance for SK Capital, and Rothschild & Co and Dentons for LISI Group.
Sectors
- Private Equity
- Medical Technology
- Contract Development and Manufacturing Organization (CDMO)
Geography
- United States – SK Capital is based in New York, and Lisi Medical operates two manufacturing sites in Minnesota.
- France – Lisi Medical operates two manufacturing sites in France, and LISI Group, the seller, is based in France.
Industry
- Private Equity – The article discusses SK Capital, a private investment firm, engaging in an acquisition deal.
- Medical Technology – Lisi Medical, the target of the acquisition, operates within the MedTech sector, producing high-precision components for medical devices.
- Contract Development and Manufacturing Organization (CDMO) – Lisi Medical is a CDMO in the MedTech industry, providing manufacturing services to medical OEMs.
Financials
- Approximately $10 billion – SK Capital's assets under management as of December 31, 2024.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| SK Capital | Bidding Company | Company | A private investment firm focused on specialty materials and life sciences. |
| LISI Group | Selling Company | Company | A company listed on Euronext, selling its Lisi Medical division. |
| Lisi Medical | Target Company | Company | A MedTech CDMO specializing in high-precision metal components for medical devices. |
| Josh Lieberman | Principal at SK Capital | Person | Involved in the acquisition discussions from SK Capital's side. |
| Aaron Davenport | Managing Director at SK Capital | Person | Commented on the strategic fit of Lisi Medical within SK Capital's portfolio. |
| Emmanuel Viellard | CEO of LISI Group | Person | Provided statements about the strategic alignment with SK Capital. |
| Kirkland & Ellis | Legal advisor to SK Capital | Company | Providing legal advisory services for the acquisition. |
| Piper Sandler & Co. | Financial advisor to SK Capital | Company | Offering financial advisory services for SK Capital in the transaction. |
| Jefferies LLC | Financial advisor to SK Capital | Company | Engaged in financial advisory for the acquisition. |
| Sycomore Corporate Finance | Financial advisor to SK Capital | Company | Providing financial advisory services to SK Capital. |
| Partners Group | Debt Financing Provider | Company | Provided committed debt financing in support of the transaction. |
| Rothschild & Co | Financial advisor to LISI Group | Company | Serving as financial advisor to LISI Group for the transaction. |
| Dentons | Legal counsel to LISI Group | Company | Acting as legal counsel to LISI Group during the acquisition process. |